Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers. 2013

Hidenori Takahashi, and Masato Okamoto, and Shigetaka Shimodaira, and Shun-ichi Tsujitani, and Masaki Nagaya, and Takefumi Ishidao, and Junji Kishimoto, and Yoshikazu Yonemitsu, and
Seren Clinic Tokyo, Tokyo, Japan. bzr06263@nifty.com

OBJECTIVE Dendritic cell (DC)-based vaccines have been expected to serve as new therapeutic approaches for advanced non-small cell lung cancers (NSCLCs); however, their clinical outcomes have not been fully elucidated. We report a single-centre clinical study analysing factors affecting the survival of patients with advanced NSCLCs who received DC vaccines pulsed with or without Wilms' tumour protein-1 (WT1) peptide. METHODS Among 62 patients with previously treated inoperable or postoperatively relapsed NSCLCs who met the inclusion criteria, DCs from 47 (76%) patients who showed HLA-A2402/0201/0206 were pulsed with one or more corresponding WT1 peptide antigens. DC vaccines were intradermally injected biweekly. RESULTS Clinical responses based on response evaluation criteria in solid tumours (RECIST) were found in 31 (50%) patients at 3 months after the first DC vaccine (complete response: 1 (1.6%), partial response: 4 (6.5%), stable disease: 26 (41.9%)). Median survival time was 27 months (82% in 1 year and 54% in 2 years) from initial diagnosis, and that was 12 months (48% in 1 year and 22% in 2 years) from the first DC vaccination. Importantly, multivariate analyses revealed that only two factors, blood haemoglobin and the use of WT1 peptides, significantly affected the overall survival of patients from both initial diagnosis and first vaccination. CONCLUSIONS This study is the first to suggest that DC vaccines pulsed with WT1 may hold a significant impact to prolong the overall survival of patients with advanced NSCLCs.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D003713 Dendritic Cells Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION). Dendritic Cells, Interdigitating,Interdigitating Cells,Plasmacytoid Dendritic Cells,Veiled Cells,Dendritic Cells, Interstitial,Dendritic Cells, Plasmacytoid,Interdigitating Dendritic Cells,Interstitial Dendritic Cells,Cell, Dendritic,Cell, Interdigitating,Cell, Interdigitating Dendritic,Cell, Interstitial Dendritic,Cell, Plasmacytoid Dendritic,Cell, Veiled,Cells, Dendritic,Cells, Interdigitating,Cells, Interdigitating Dendritic,Cells, Interstitial Dendritic,Cells, Plasmacytoid Dendritic,Cells, Veiled,Dendritic Cell,Dendritic Cell, Interdigitating,Dendritic Cell, Interstitial,Dendritic Cell, Plasmacytoid,Interdigitating Cell,Interdigitating Dendritic Cell,Interstitial Dendritic Cell,Plasmacytoid Dendritic Cell,Veiled Cell

Related Publications

Hidenori Takahashi, and Masato Okamoto, and Shigetaka Shimodaira, and Shun-ichi Tsujitani, and Masaki Nagaya, and Takefumi Ishidao, and Junji Kishimoto, and Yoshikazu Yonemitsu, and
January 2006, Zhongguo fei ai za zhi = Chinese journal of lung cancer,
Hidenori Takahashi, and Masato Okamoto, and Shigetaka Shimodaira, and Shun-ichi Tsujitani, and Masaki Nagaya, and Takefumi Ishidao, and Junji Kishimoto, and Yoshikazu Yonemitsu, and
April 2022, Journal of clinical medicine,
Hidenori Takahashi, and Masato Okamoto, and Shigetaka Shimodaira, and Shun-ichi Tsujitani, and Masaki Nagaya, and Takefumi Ishidao, and Junji Kishimoto, and Yoshikazu Yonemitsu, and
February 2010, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery,
Hidenori Takahashi, and Masato Okamoto, and Shigetaka Shimodaira, and Shun-ichi Tsujitani, and Masaki Nagaya, and Takefumi Ishidao, and Junji Kishimoto, and Yoshikazu Yonemitsu, and
November 2010, Gan to kagaku ryoho. Cancer & chemotherapy,
Hidenori Takahashi, and Masato Okamoto, and Shigetaka Shimodaira, and Shun-ichi Tsujitani, and Masaki Nagaya, and Takefumi Ishidao, and Junji Kishimoto, and Yoshikazu Yonemitsu, and
May 2019, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
Hidenori Takahashi, and Masato Okamoto, and Shigetaka Shimodaira, and Shun-ichi Tsujitani, and Masaki Nagaya, and Takefumi Ishidao, and Junji Kishimoto, and Yoshikazu Yonemitsu, and
September 2013, British journal of cancer,
Hidenori Takahashi, and Masato Okamoto, and Shigetaka Shimodaira, and Shun-ichi Tsujitani, and Masaki Nagaya, and Takefumi Ishidao, and Junji Kishimoto, and Yoshikazu Yonemitsu, and
January 2015, Asian Pacific journal of cancer prevention : APJCP,
Hidenori Takahashi, and Masato Okamoto, and Shigetaka Shimodaira, and Shun-ichi Tsujitani, and Masaki Nagaya, and Takefumi Ishidao, and Junji Kishimoto, and Yoshikazu Yonemitsu, and
August 2016, Journal of cancer research and clinical oncology,
Hidenori Takahashi, and Masato Okamoto, and Shigetaka Shimodaira, and Shun-ichi Tsujitani, and Masaki Nagaya, and Takefumi Ishidao, and Junji Kishimoto, and Yoshikazu Yonemitsu, and
September 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Hidenori Takahashi, and Masato Okamoto, and Shigetaka Shimodaira, and Shun-ichi Tsujitani, and Masaki Nagaya, and Takefumi Ishidao, and Junji Kishimoto, and Yoshikazu Yonemitsu, and
July 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!